April 17, 2024 |
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.
For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.
This content was provided by Inizio
Latest Content from Inizio
The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers…
Utilising the benefits of mobile technology
Presenting a window on the world of your customer
Conducting research in one of the world’s largest pharma markets
The process of demand calibration of preference share (down-weighting) is often a proprietary “black box” technique, which can mean that the client is unsure how the calibrated figure has been…
Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?
Published in eye for pharma 30 January by Marc Yates
Published in eye for pharma 12 December by Marc Yates
Published in Eye for Pharma 10 November by Marc Yates
Pegasus, the UK’s leading independent health communications consultancy, picked up the “Specialist Consultancy of the Year” award at the PRCA Awards 2014.
